A recent GlobalData analysis revealed a decline in sales volume for Sexually Transmitted Infection (STI) testing in US healthcare sites during the first half of 2025. Sales for chlamydia/gonorrhoea tests decreased by 1.7% compared to the first half of 2024.
More significantly, tests targeting bacterial vaginosis saw a substantial decrease of 27.8% year-over-year in sales volume. These declines impact key diagnostic areas where Hologic offers its molecular diagnostic assays, such as the BV/CV/TV test.
This industry trend suggests potential headwinds for Hologic's molecular diagnostics business, which has seen strong growth from its BV/CV/TV assay. Investors will monitor how this broader market decline affects the company's future performance in these segments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.